Company Description
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States.
The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications.
Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 2013 |
| IPO Date | Mar 24, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Gabriele Marco Antonio Cerrone M.B.A. |
Contact Details
Address: 3rd Floor, 11-12 St. James's Square London, England, X0 SW1Y 4LB United Kingdom | |
| Phone | 0044(0) 207-495-2379 |
| Website | tizianalifesciences.com |
Stock Details
| Ticker Symbol | TLSA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001723069 |
| CUSIP Number | 88875G101 |
| ISIN Number | BMG889121031 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gabriele Marco Antonio Cerrone M.B.A. | Founder, Executive Chairman and Interim Chief Executive Officer |
| Dr. Andrea Brancale | Scientific Founder |
| Richard Clarkson Ph.D. | Scientific Founder |
| Andrew Westwell Ph.D. | Scientific Founder |
| Keeren Shah | Chief Financial Officer |
| Dr. Matthew W. Davis M.D., R.Ph. | Chief Operating Officer and Chief Medical Officer |
| Dr. William A. Clementi Ph.D., Pharm.D. | Chief Development Officer |
| Dr. Napoleone Ferrara M.D. | Member of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 28, 2024 | 6-K | Report of foreign issuer |
| Jun 26, 2024 | 6-K | Report of foreign issuer |
| Jun 11, 2024 | 6-K | Report of foreign issuer |
| Jun 6, 2024 | 6-K | Report of foreign issuer |
| Jun 4, 2024 | 6-K | Report of foreign issuer |
| May 30, 2024 | 6-K | Report of foreign issuer |
| May 13, 2024 | 6-K | Report of foreign issuer |
| May 10, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Apr 30, 2024 | NT 20-F | Notification of inability to timely file Form 20-F |
| Apr 25, 2024 | 6-K | Report of foreign issuer |